The fastest-growing and largest of the 20 sized Pharmaceuticals markets in Kenya, 2023 to 2033, with active clinical trials.
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Biosimilars | $26 Mn | $261 Mn | 26% | 0 |
| 2 | Cell Based Immunotherapy | $12 Mn | $101 Mn | 24.1% | 23 |
| 3 | Cannabidiol (CBD) | $15 Mn | $80 Mn | 17.9% | 0 |
| 4 | Cannabis | $24 Mn | $93 Mn | 14.6% | 0 |
| 5 | Atopic Dermatitis Drugs | $8 Mn | $27 Mn | 13.3% | 0 |
| 6 | Oncology/Cancer Drugs | $124 Mn | $307 Mn | 9.5% | 15 |
| 7 | Anti-Aging | $62 Mn | $149 Mn | 9.2% | 0 |
| 8 | Diabetes Management | $55 Mn | $120 Mn | 8.2% | 2 |
| 9 | Alzheimer Drugs | $3.5 Bn | $7.5 Bn | 7.9% | 0 |
| 10 | Contraceptives Drugs | $18 Mn | $38 Mn | 7.9% | 4 |
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Alzheimer Drugs | $3.5 Bn | $7.5 Bn | 7.9% | 0 |
| 2 | Oncology/Cancer Drugs | $124 Mn | $307 Mn | 9.5% | 15 |
| 3 | Anti-Aging | $62 Mn | $149 Mn | 9.2% | 0 |
| 4 | Diabetes Management | $55 Mn | $120 Mn | 8.2% | 2 |
| 5 | Gastrointestinal Drugs | $38 Mn | $66 Mn | 5.7% | 10 |
| 6 | Asthma & COPD Drugs | $35 Mn | $57 Mn | 5.1% | 1 |
| 7 | Biosimilars | $26 Mn | $261 Mn | 26% | 0 |
| 8 | Cannabis | $24 Mn | $93 Mn | 14.6% | 0 |
| 9 | HIV Drugs | $21 Mn | $41 Mn | 6.9% | 45 |
| 10 | Contraceptives Drugs | $18 Mn | $38 Mn | 7.9% | 4 |
2033 values are projected from the 2023 size and the CAGR. Each market name opens its report. Active trials: recruiting, about to start or running.
Biosimilars grows fastest, at 26% a year from 2023 to 2033, ahead of Cell Based Immunotherapy (24.1%).
Alzheimer Drugs is the largest, worth about $3.5 Bn in 2023 and $7.5 Bn by 2033 (projected).
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide.